ARCH and ACHFF Related Headlines
Go Back- Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
- Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
- Arch Biopartners closes $600,000 private placement
- Arch Biopartners Closes Non-Brokered Private Placement
- Arch Biopartners arranges $500,000 private placement with company officer
- Arch Biopartners Arranges Non-Brokered Private Placement
- Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
ARCH and ACHFF Related Press Releases
Go Back- Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
- Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
- Arch Biopartners Closes Non-Brokered Private Placement
- Arch Biopartners Arranges Non-Brokered Private Placement
- Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
